| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1023/A:1008634911114 |
| P698 | PubMed publication ID | 9762727 |
| P2093 | author name string | D J Touw | |
| P433 | issue | 4 | |
| P921 | main subject | cystic fibrosis | Q178194 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 149-160 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | International Journal of Clinical Pharmacy | Q15759467 |
| P1476 | title | Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis | |
| P478 | volume | 20 |
| Q41474199 | Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients |
| Q42764712 | Acute renal failure in people with cystic fibrosis |
| Q40729344 | Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? |
| Q33886807 | Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient |
| Q39278957 | Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. |
| Q40911068 | Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients |
| Q84959439 | Decreased renal accumulation of aminoglycoside reflects defective receptor-mediated endocytosis in cystic fibrosis and Dent's disease |
| Q56570517 | Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice- to once-daily tacrolimus oral administration |
| Q26853629 | Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics |
| Q27004711 | Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis |
| Q41139947 | Metastatic bladder cancer presenting with persistent hematuria in young man with cystic fibrosis |
| Q64939222 | Multidrug-Resistant Organisms: Considerations in Antibiotic Selection and Administration. |
| Q37287648 | Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. |
| Q34381321 | Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens |
| Q45262881 | Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial |
| Q37094805 | One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation |
| Q28069334 | Optimizing the Clinical Use of Vancomycin |
| Q40829169 | Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. |
| Q38636242 | Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Cystic Fibrosis |
| Q35191579 | Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis |
| Q89122759 | Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis |
| Q57052026 | Pharmacokinetics of Intravenous Isavuconazole in Solid Organ Transplant Recipients |
| Q89143136 | Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis |
| Q37248489 | Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature |
| Q37358630 | Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation |
| Q37274659 | Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. |
| Q34824085 | Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. |
| Q36364174 | Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile |
| Q38871662 | Relationship between vancomycin dosage and serum trough vancomycin concentrations in pediatric patients with cystic fibrosis |
| Q30479961 | Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis |
| Q26822417 | Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patients |
| Q35878860 | Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers |
| Q46504944 | Tobramycin dosing in cystic fibrosis |
| Q38625059 | Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia |
Search more.